Bellevue Group AG
- SEC CIK
- 0001674546
- Latest filing
- Aug 14, 2026
Holdings in Q1 2025
Holdings as of Mar 31, 2025, filed May 14, 2025. Long positions only; changes compare share counts with Q4 2024.
- Positions
- 148
- −12 vs. Q4 2024
- Portfolio value
- $4.46B
- −$732.1M (−14.1%) vs. Q4 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| HCAHCA Healthcare, Inc. | COM | 61,807 | $21.4M | 0.5% | −76−0.1% | Reduced | History |
| ALGNAlign Technology Inc | COM | 150,993 | $24.0M | 0.5% | −9,010−5.6% | Reduced | History |
| PRCTPROCEPT BioRobotics Corp | COM | 414,923 | $24.2M | 0.5% | −47,971−10.4% | Reduced | History |
| GMEDGlobus Medical Inc | Stock | 332,336 | $24.3M | 0.5% | −30,643−8.4% | Reduced | History |
| STESTERIS plc | SHS USD | 109,887 | $24.9M | 0.6% | 00.0% | Unchanged | History |
| MOHMolina Healthcare, Inc. | COM | 75,895 | $25.0M | 0.6% | −6,256−7.6% | Reduced | History |
| EXASExact Sciences Corp | COM | 579,074 | $25.1M | 0.6% | −114,982−16.6% | Reduced | History |
| AMGNAmgen Inc | Stock | 80,935 | $25.2M | 0.6% | −8,305−9.3% | Reduced | History |
| DHRDanaher Corp | Stock | 124,321 | $25.5M | 0.6% | +4,399+3.7% | Added | History |
| BMRNBiomarin Pharmaceutical Inc | COM | 368,373 | $26.0M | 0.6% | +39,352+12.0% | Added | History |
| VEEVVeeva Systems Inc | Stock | 113,250 | $26.2M | 0.6% | −14,325−11.2% | Reduced | History |
| ABBVAbbVie Inc. | Stock | 135,240 | $28.3M | 0.6% | +89,981+198.8% | Added | History |
| COOCooper Companies, Inc. | COM | 357,025 | $30.1M | 0.7% | −1050.0% | Reduced | History |
| EWTXEdgewise Therapeutics, Inc. | COM | 1,428,929 | $31.4M | 0.7% | 00.0% | Unchanged | History |
| TMOThermo Fisher Scientific Inc. | Stock | 64,232 | $32.0M | 0.7% | +3,270+5.4% | Added | History |
| IDXXIDEXX Laboratories Inc | COM | 76,897 | $32.3M | 0.7% | −380.0% | Reduced | History |
| ZBHZimmer Biomet Holdings, Inc. | Stock | 291,346 | $33.0M | 0.7% | −2,275−0.8% | Reduced | History |
| WVEWave Life Sciences, Inc. | SHS | 4,094,458 | $33.1M | 0.7% | 00.0% | Unchanged | History |
| LLYEli Lilly & Co | Stock | 43,647 | $36.0M | 0.8% | −1,818−4.0% | Reduced | History |
| IMCRImmunocore Holdings plc | ADS | 1,221,794 | $36.3M | 0.8% | +16,330+1.4% | Added | History |
| RMDResmed Inc | COM | 165,802 | $37.1M | 0.8% | +5,009+3.1% | Added | History |
| CICigna Group | Stock | 117,535 | $38.7M | 0.9% | −7,670−6.1% | Reduced | History |
| GEHCGE HealthCare Technologies Inc. | Stock | 524,414 | $42.3M | 0.9% | 00.0% | Unchanged | History |
| MRNAModerna, Inc. | Stock | 1,518,122 | $43.0M | 1.0% | −82,755−5.2% | Reduced | History |
| BEAMBeam Therapeutics Inc. | COM | 2,395,930 | $46.8M | 1.0% | +877,809+57.8% | Added | History |
| BHVNBiohaven Ltd. | COM | 2,040,853 | $49.1M | 1.1% | 00.0% | Unchanged | History |
| AKROAkero Therapeutics, Inc. | COM | 1,250,666 | $50.6M | 1.1% | +1,250,666 | New | History |
| PENPenumbra Inc | COM | 204,517 | $54.7M | 1.2% | −33,536−14.1% | Reduced | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 3,071,615 | $55.7M | 1.2% | 00.0% | Unchanged | History |
| EWEdwards Lifesciences Corp | Stock | 971,969 | $70.4M | 1.6% | −125,879−11.5% | Reduced | History |
| PODDInsulet Corp | Stock | 271,286 | $71.2M | 1.6% | −50,631−15.7% | Reduced | History |
| DXCMDexcom Inc | COM | 1,064,108 | $72.7M | 1.6% | +19,064+1.8% | Added | History |
| BDXBecton Dickinson & Co | Stock | 344,311 | $78.9M | 1.8% | +6,763+2.0% | Added | History |
| SRRKScholar Rock Holding Corp | COM | 2,506,890 | $80.6M | 1.8% | −3,800−0.2% | Reduced | History |
| MDTMedtronic plc | Stock | 938,355 | $84.3M | 1.9% | −104,593−10.0% | Reduced | History |
| UNHUnitedHealth Group Inc | Stock | 164,742 | $86.3M | 1.9% | +5,029+3.1% | Added | History |
| AGIOAgios Pharmaceuticals, Inc. | COM | 3,515,150 | $103.0M | 2.3% | 00.0% | Unchanged | History |
| INCYIncyte Corp | COM | 2,091,780 | $126.7M | 2.8% | −65,698−3.0% | Reduced | History |
| RVMDRevolution Medicines, Inc. | COM | 4,374,300 | $154.7M | 3.5% | −12,600−0.3% | Reduced | History |
| BSXBoston Scientific Corp | Stock | 1,951,020 | $196.8M | 4.4% | −184,275−8.6% | Reduced | History |
| VRTXVertex Pharmaceuticals Inc | Stock | 413,071 | $200.3M | 4.5% | −74,363−15.3% | Reduced | History |
| NBIXNeurocrine Biosciences Inc | Stock | 1,820,000 | $201.3M | 4.5% | 00.0% | Unchanged | History |
| ABTAbbott Laboratories | Stock | 1,556,129 | $206.4M | 4.6% | −132,531−7.8% | Reduced | History |
| ALNYAlnylam Pharmaceuticals, Inc. | COM | 768,147 | $207.4M | 4.6% | −2,121−0.3% | Reduced | History |
| ISRGIntuitive Surgical Inc | COM NEW | 425,746 | $210.9M | 4.7% | −38,631−8.3% | Reduced | History |
| SYKStryker Corp | Stock | 566,597 | $210.9M | 4.7% | +46,571+9.0% | Added | History |
| IONSIonis Pharmaceuticals Inc | COM | 7,853,198 | $236.9M | 5.3% | −15,502−0.2% | Reduced | History |
| ARGXArgenx SE | SPONSORED ADR | 578,874 | $342.6M | 7.7% | −14,310−2.4% | Reduced | History |
Sold out since Q4 2024 (22)
Positions held at the end of Q4 2024 that are gone from this filing.
| Security | Class | Shares in Q4 2024 | Value in Q4 2024 | % of portfolio in Q4 2024 | History |
|---|---|---|---|---|---|
| ITCIIntra-Cellular Therapies, Inc. | COM | 2,440,240 | $203.8M | 3.9% | History |
| ARVNArvinas, Inc. | COM | 2,389,600 | $45.8M | 0.9% | History |
| TNDMTandem Diabetes Care Inc | COM NEW | 782,456 | $28.2M | 0.5% | History |
| SAGESage Therapeutics, Inc. | COM | 4,460,693 | $24.2M | 0.5% | History |
| CRLCharles River Laboratories International, Inc. | COM | 50,327 | $9.29M | 0.2% | History |
| FATEFate Therapeutics Inc | COM | 4,839,779 | $7.99M | 0.2% | History |
| TERNTerns Pharmaceuticals, Inc. | COM | 1,061,753 | $5.88M | 0.1% | History |
| OMCLOmnicell, Inc. | COM | 94,740 | $4.22M | 0.1% | History |
| ACCDAccolade, Inc. | COM | 615,509 | $2.11M | <0.1% | History |
| GOOGAlphabet Inc. | Stock | 6,000 | $1.14M | <0.1% | History |
| AMRXAmneal Pharmaceuticals, Inc. | COM STK CL A | 100,414 | $795.3K | <0.1% | History |
| VKTXViking Therapeutics, Inc. | COM | 12,939 | $520.7K | <0.1% | History |
| XENEXenon Pharmaceuticals Inc. | COM | 8,200 | $321.4K | <0.1% | History |
| DNLIDenali Therapeutics Inc. | COM | 15,700 | $320.0K | <0.1% | History |
| ROIVRoivant Sciences Ltd. | SHS | 24,000 | $283.9K | <0.1% | History |
| BPMCBlueprint Medicines Corp | COM | 3,200 | $279.1K | <0.1% | History |
| RAREUltragenyx Pharmaceutical Inc. | COM | 4,000 | $168.3K | <0.1% | History |
| KNSAKiniksa Pharmaceuticals International, plc | ORD SHS CL A | 8,100 | $160.2K | <0.1% | History |
| NRIXNurix Therapeutics, Inc. | COM | 8,000 | $150.7K | <0.1% | History |
| VCYTVeracyte, Inc. | COM | 3,600 | $142.6K | <0.1% | History |
| KURAKura Oncology, Inc. | COM | 13,600 | $118.5K | <0.1% | History |
| AUTLAutolus Therapeutics plc | SPON ADS | 41,500 | $97.5K | <0.1% | History |